First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna® Cleared by Health Canada PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation received regulatory approval from Health Canada for the MRDx® BCR-ABL Test, a quantitative diagnostic...

MolecularMD and Genoptix Enter into a Definitive Agreement  to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna® PORTLAND, Ore. and CARLSBAD, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation and Genoptix, Inc. announced today that they have entered into an exclusive agreement to market and...

MolecularMD obtains FDA Authorization for the MRDx® BCR-ABL Test as a Companion Diagnostic for Treatment-Free Remission in Ph+ CML-CP Patients Treated with Tasigna PORTLAND, Ore. and CAMBRIDGE, Mass., Dec. 22, 2017 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a  diagnostics company that enables the development and commercialization of precision medicines in...